LV15082A - Cream for restoring epidermal lipid barrier of the facial skin, neck and decollette area in metabolic syndrome patients - Google Patents

Cream for restoring epidermal lipid barrier of the facial skin, neck and decollette area in metabolic syndrome patients Download PDF

Info

Publication number
LV15082A
LV15082A LVP-15-90A LV150090A LV15082A LV 15082 A LV15082 A LV 15082A LV 150090 A LV150090 A LV 150090A LV 15082 A LV15082 A LV 15082A
Authority
LV
Latvia
Prior art keywords
skin
cream
patients
metabolic syndrome
composition
Prior art date
Application number
LVP-15-90A
Other languages
Latvian (lv)
Other versions
LV15082B (en
Inventor
Jūlija VOICEHOVSKA
Jana Janovska
Irēna Daberte
Vladimirs Voicehovskis
Andrejs ŠĶESTERS
Alise Silova
Sergejs Babikovs
Olga Zubova
Dagmāra Sprudža
Jānis Ķīsis
Ludmila Ivanova
Original Assignee
Rīgas Stradiņa Universitāte
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rīgas Stradiņa Universitāte filed Critical Rīgas Stradiņa Universitāte
Priority to LVP-15-90A priority Critical patent/LV15082B/en
Priority to PCT/LV2015/000006 priority patent/WO2017034384A1/en
Priority to EP15902371.2A priority patent/EP3439616A4/en
Publication of LV15082A publication Critical patent/LV15082A/en
Publication of LV15082B publication Critical patent/LV15082B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355Tocopherols, e.g. vitamin E
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/01Hydrocarbons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/31Hydrocarbons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34Alcohols
    • A61K8/342Alcohols having more than seven atoms in an unbroken chain
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34Alcohols
    • A61K8/345Alcohols containing more than one hydroxy group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36Carboxylic acids; Salts or anhydrides thereof
    • A61K8/368Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37Esters of carboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37Esters of carboxylic acids
    • A61K8/375Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/39Derivatives containing from 2 to 10 oxyalkylene groups
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/58Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing atoms other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur or phosphorus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67Vitamins
    • A61K8/678Tocopherol, i.e. vitamin E
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/84Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
    • A61K8/86Polyethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Emergency Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Cosmetics (AREA)

Abstract

Invention relates to the field of dermatology and cosmetology. A composition of a cream for taking care of epidermal lipid barrier of the facial skin, neck and decollette area is provided for. The composition contains seleno-L-methionine, alpha-tocopherol acetate, squalane and other components characteristic to such creams in given proportions.

Description

IZGUDROJUMA APRAKSTSDESCRIPTION OF THE INVENTION

Izgudrojums attiecas uz medicīnu, ir saistīts ar ģimenes medicīnu (ģimenes ārstu praksi), terapiju, endokrinoloģiju, gerontoloģiju, dermatoloģiju un kosmetoloģiju, kā arī risina sejas ādas, kakla un dekoltē zonas epidermālās lipīdu barjeras atjaunošanas problēmas pacientiem ar metabolisko sindromu.The invention relates to medicine, is related to family medicine (family practitioners), therapy, endocrinology, gerontology, dermatology and cosmetology, as well as solves the problems of regeneration of epidermal lipid barrier in the skin of the face, neck and décolleté in patients with metabolic syndrome.

TEHNIKAS LĪMENISTECHNICAL LEVEL

Metaboliskais sindroms (MS) - izmaiņu komplekss, kas saistīts ar vielmaiņas traucējumiem, kura gadījumā attīstās nejutība pret insulīnu, tiek traucēta glikozes uzņemšana šūnās. Metaboliskajam sindromam seko dažādu saslimšanu komplekss: hipertonija, aptaukošanās, sirds išēmiskā slimība, 2. tipa cukura diabēts. Metaboliskā sindroma attīstību raksturo vidukļa apkārtmēra palielināšanās: vīriešiem - vairāk par 102 cm, sievietēm - vairāk par 88 cm. Arteriālā asinsspiediena līmenis -135/85 mmHg. Asinīs kostatē augstu lipīdu peroksidācijas produktu saturu. Oksidanti sāk aktivēt šūnu reakcijas, kas sagrauj olbaltumvielas, lipīdus, DNS. Tiek traucēta ādas baijerfunkcija un tā intensīvāk zaudē mitrumu, kļūst sausa, kas izraisa pārmērīgu ādas zvīņošanos, ādas ragveida slāņa sabiezējumu, piešķir ādai pelēcīgu nokrāsu, sekmē dažādu ādas saslimšanu attīstību: seboreja, atrofiskais dermatīts, psoriāze, ekzēma u.c. saslimšanas [ 1 ].Metabolic Syndrome (MS) - a complex of changes associated with metabolic disorders in which insulin resistance develops, impairing the uptake of glucose in cells. Metabolic syndrome is followed by a complex of different diseases: hypertension, obesity, ischemic heart disease, type 2 diabetes. The development of metabolic syndrome is characterized by an increase in the waist circumference: more than 102 cm for men and more than 88 cm for women. Arterial blood pressure -135/85 mmHg. High levels of lipid peroxidation products in the blood. Oxidants start to activate cellular reactions that destroy proteins, lipids, DNA. The skin's Bavarian function is disturbed and it loses its moisture more intensively, it becomes dry, causing excessive skin flaking, thickening of the skin's horny layer, giving the skin a gray tinge, contributing to the development of various skin diseases: seborrhea, atrophic dermatitis, psoriasis, eczema, etc. diseases [1].

Cilvēka ķermeņa āda ir sarežģīta bioloģiska audu sistēma, kum veido epiderma, derma un zemādas tauku šūnaūdi. Epidermas bazālajā slānī atrodas melanocīti un Langerhansa šūnas, kas izvietotas uz bazālās membrānas. Epidermas pamatslānī atrodas protoplazmas šķiedras, granulveida slāni veido šūnas ar keratohialīna kompleksiem. Derma - ādas savienojošā daļa, galvenais ādas apjoms. Derma ar bazālo membrānu norobežota no epidermas [2].The human body skin is a complex biological tissue system, composed of epidermis, dermis and subcutaneous fat cells. The epidermal basal layer contains melanocytes and Langerhans cells located on the basal membrane. In the epidermal base layer, protoplasm fibers are present, the granular layer forms cells with keratohialin complexes. Derma - the connecting part of the skin, the main skin volume. Derma with basal membrane delimited from the epidermis [2].

Epidermas ārējo daļu klāj raga slānis, uz kura izveidota ūdens-lipīdu mantija ar vāji skābu vidi - skābuma līmenis 4,5-5,5 pH. Šāds skābuma līmenis rada baktericīdu iedarbību un sekmē lipīdu sintēzi. Ādas skābes īpašības saistītas ar sviedriem un ādas taukiem. Daudzie uz ādas nokļūstošie mikrobi iet bojā 20-30 minūšu laikā [3]. Ūdens-lipīdu mantija veido epidermālo baijeru, kas sastāv no ragveida šūnām - zvīņām, kuras tiek sauktas par komeocītiem, starp kuriem izvietoti epidermālie starpšūnu lipīdi - keramīdi. Keramīdi savieno komeocītus necaurejamā, 2 viengabalainā epidermālā barjerā. Keramīdu molekulām ir polāra struktūra, jo tām ir hidrofilas galvas (dod priekšroku ūdenim) un lipofilas astes (dod priekšroku taukiem). Epidermālā lipīdu barjera neļauj iekļūt ādā kaitīgām vielām, iesaistās dermas ūdens hemostāzes regulēšanā. Lipīdu barjera sastāv no holesterīna, keramīdiem, nepiesātinātām taukskābēm (Omega-3, Omega-6). Nepiesātinātajām taukskābēm Omega-3, Omega-6 piemīt pretiekaisuma iedarbība, tās stimulē Langerhansa šūnas un nostiprina epidermālo lipīdu barjeru [4]. Brīvās taukskābes izvietotas lipīdu slānī, apkārt keramīdiem, tās sekmē ādas ūdens necaurlaidības funkciju, veido ūdens-eļļas emulsiju. Ja lipīdu barjera tiek traucēta, tad ādā iekļūst mikroorganismi, ķīmiskie un citi eksogēnie agresīvie faktori. Ādai ir imūno šūnu sistēma, galvenā loma ir Langerhansa šūnām (2-5 % šūnu epidermas). Langerhansa šūnas piedalās baktēriju iznīcināšanā un ierosina imūno atbildi, kurā piedalās dermālās dendritu šūnas, epidermālie makrofagi u.c. Ādas novecošanās saistīta ar imūnās sistēmas stāvokli [5]. Pēc 25 gadu vecuma organismā sāk darboties dabiskas novecošanās mehānisms: samazinās ādas makrofagu daudzums, oksidanti sāk aktivēt šūnu reakcijas, radot olbaltumvielu, lipīdu un DNS traucējumus. īpaši aktīvi ādas paātrinātas, patoloģiskas novecošanās process sākas slimniekiem ar metabolisko sindromu (MS). Zināms, ka metabolisko sindromu pavada latents iekaisums, kas izraisa peroksidācijas procesu aktivizāciju. Lipīdu peroksidācijas produktu uzkrāšanās, lipoproteīnu un lipīdu slāņa lipīdu oksidatīvie bojājumi izpaužas kā ādas struktūras komponentu morfoloģiskās izmaiņas [6]. Aizsardzības sistēma, ko veido antioksidanti, pacientiem ar metabolisko sindromu ir novājināta un/vai neefektīvā. Metaboliskā sindroma gadījumā rodas oksidatīvais stress: tiek traucēta keratinocītu veidošanās, novērojams transepidermālā ūdens pastiprināts zudums, ādas sausums, plaisas un erozijas. Izmaiņas izraisa ādas mikrofloras disbalansu un sēnīšu skaita pieaugumu, papilomu rašanos. Ādas epidermālās lipīdu barjeras atjaunošana pacientiem ar metabolisko sindromu ir īpaši aktuāls uzdevums [7]. 1. tabula - ādas epidermālās lipīdu barjeras traucējumu analīze un to noteikšanas metodes. 3 1. tabula Ādas epidermālās lipīdu barjeras traucējumu analīze un to noteikšanas metodes Traucējumu klīniskās izpausmes Transepidermālā ūdens zuduma paātrinājums (tevametrija) un ūdens saturs epidermas raga slānī (korneometrija). Ādas sausums, lobīšanās, plaisas, raga slāņa sabiezēšana (hiperkeratoze). Ādas skābju-sārmu līdzsvara izmaiņas, pH (pH-metrijas sensors). Papilomas, ādas inficēšanās, lipīdu sintēzes traucējumi. Ādas reljefa un morfoloģiskais stāvoklis (dermatoskopija, mikrofotogrāfija). Ādas turgors, mikroreļjefs, papilomas, elastības samazināšanās, elastoze. Pigmentācija un lobīšanās (siaskopija, meksametrija). Lentigo orgāni un/vai pigmentācijas neviendabīgums (dispigmentācija). Ādas imunitāte (gaismas mikroskopija, imūnhistoķīmija). Imūnkompetentās Langerhansa šūnas, Birbeka granulas, baktēriju un/vai vīrusu, papilomu iekļūšana ādā. Ādas dažādu zonu taukainība (sebumetrija). Āda sausa, taukaina, normāla, kombinēta. Epidermas proliferācijas ātrums (mikrofotografešana). Komeocītu izmēri, lielās komeocītu šūnas ādas dehidratācijas gadījumā. LV 15082 Ādas epidermālās lipīdu barjeras traucējumu analīzi veic ar dermatoskopijas starpniecību (ādas pH, mitruma/sausuma, taukainības novērtēšana) un siaskopijas starpniecību (dispigmentācijas izvērtējums un mikroreljefa izpēte). Transepidermālā ūdens zuduma mērīšanai izmanto sensoru Tewameter® TM 300, Courage + Khazaka electronic GmbH, Vācija. Siaskopijas veikšanai izmanto siaskopu MoleView SIAscope V Handset, Astron, Lielbritānija. Dermatoskopijas veikšanai izmanto dermatoskopu HEINE alpha + Heine Optotechnic, Vācija. Tos izmantojot, analizē uz datoru pārsūtītos rādītājus, vienlaikus veicot vairāku epidermālās lipīdu barjeras stāvokļa atspoguļojošo raksturlielu analīzi [8-11]: • Korneometrija (ādas mitrums, ūdens saturs epidermas raga slānī), izmanto ar dermatoskopa palīdzību. Komeometrijas princips pamatojas uz dielektriskās vides elektriskās kapacitātes mērīšanu. Jebkādas dielektriskās konstantes izmaiņas, kas saistītas ar ūdens satura svārstībām ādas virsējos slāņos, izraisa mērīšanas sistēmas kapacitatīvo raksturlielumu izmaiņas. Mitrināšanu vērtē pēc skalas. Par pamatu tiek ņemta ūdens dielektriskā kapacitāte - 81, izšķir 4-6 ādas mitrinājuma pakāpes (ļoti augsta mitrinājuma pakāpe - 45,0-99,9; augsta, normāla - 4 35,1-40,0; pazemināta, zema-20,1-29,9; atūdeņota - zemāka par 20,0). • Transepidermālā ūdens zuduma mērīšana, mērījums ūdens iztvaikošanai no ādas virsmas, kas pamatojas uz difūzijas principu atvērtā kamerā. Metode pamatojas uz ūdens parciālā spiediena mērīšanu slēgtā kamerā ar vienu mitruma sensoru. Noteiktā laika periodā mēra parciālā spiediena pieaugumu kamerā. • Skābes-bāzes līdzsvars, pH-metrija. pH-metrijas sensorā izmanto ļoti precīzu stikla elektrodu. • Sebumetrija, sebumetrijas metodi izmanto, lai dažādās zonās noteiktu ādas taukainību. Metodes pamatā fotometrijas princips. Lieto polimēra plēvi, kura ir selektīvs lipīdu absorbents, kuru pirms un pēc raidītāja aplikācijas uz ādas virsmas ievieto fotometrā. Mērīšanas rezultāti tiek izteikti mkg/cm. Sebumetrijas rādītāji nav atkarīgi no ādas mitruma. Taukainības sensors (sponžs) sastāv no trijiem komponentiem, viens no tiem ir papīrs - matēts, jutigs pret tauku sastāvdaļām, kurš reaģē tikai uz sebumu (ādas taukiem), absorbē to, mikroprocesors apstrādā iegūtās krāsas izmaiņas, nosakot ādas tipu: sausa, normāla, taukaina vai kombinēta. • Meksametrija (dažādu ādas pigmentu satura novērtējums), ļauj izmērīt melatonīna pigmenta daudzumu ādā un eritēmas pakāpi. Mērīšanas princips pamatots uz to, ka āda dažādās spektra zonās uzsūc dažāda garuma gaismas viļņus. Meksametrijas metode ir īpaši lietderīga, veicot ultravioletā bojājuma izraisītu alerģijas vai iekaisuma reakcijas skaitlisko izvērtēšanu. • Mikroreljefa izpēte ar mikrofotografēšanu - mūsdienīgas ciparu aparatūras izmantošana ādas virsmas reljefa un mikrostruktūras izvērtēšanai (krunkainība, gludums, raupjums) ar sekojošu attēlu saglabāšanu un iespēju salīdzināt, kā arī analizēt mērījumus ārstēšanas kursa laikā. Ādas lobīšanās galvenokārt atkarīga no epidermas proliferācijas ātruma, kā arī no ūdems līdzsvara. Normai atbilstoši aizejošie komeocīti ir apmēram vienāda, neliela izmēra. Apjomīgais lielo šūnu skaits liecina par ādas bojājumu un dehidratizāciju.The outer part of the epidermis is covered by a layer of horn, on which a water-lipid mantle with a weak acidic environment is formed - a pH of 4.5-5.5. This level of acidity produces bactericidal activity and promotes lipid synthesis. Skin acid properties are associated with sweat and skin fat. Many microbes that get on the skin die in 20-30 minutes [3]. A water-lipid mantle forms an epidermal bay, consisting of horny cells - scales, called comaocytes, among which are epidermal intercellular lipids - ceramides. The ceramides bind the comocytes in an impermeable, 2-piece, epidermal barrier. Ceramic molecules have a polar structure because they have hydrophilic heads (prefer water) and lipophilic tails (prefer fats). The epidermal lipid barrier prevents the penetration of harmful substances into the skin, engages in the regulation of dermal water hemostasis. The lipid barrier consists of cholesterol, ceramides, unsaturated fatty acids (Omega-3, Omega-6). Omega-3 unsaturated fatty acids have anti-inflammatory effects, stimulate Langerhans cells and strengthen the epidermal lipid barrier [4]. Free fatty acids are placed in the lipid layer around the ceramides, they contribute to the water tightness of the skin, form a water-oil emulsion. If the lipid barrier is disturbed, microorganisms, chemical and other exogenous aggressive factors enter the skin. The skin has an immune cell system, with Langerhans cells playing a key role (2-5% cellular epidermis). Langerhans cells are involved in the destruction of bacteria and initiate an immune response involving dermal dendritic cells, epidermal macrophages, etc. Skin aging is associated with the state of the immune system [5]. After the age of 25, the body has a mechanism of natural aging: the amount of macrophages in the skin is reduced, oxidants start to activate cellular reactions, causing protein, lipid and DNA disturbances. particularly active skin accelerated, pathological aging process begins in patients with metabolic syndrome (MS). It is known that metabolic syndrome is accompanied by latent inflammation that causes the activation of peroxidation processes. Accumulation of lipid peroxidation products, lipoprotein and lipid lipid oxidative lesions are manifested as morphological changes in skin structure components [6]. The antioxidant protective system in patients with metabolic syndrome is weakened and / or ineffective. In the case of metabolic syndrome, oxidative stress occurs: keratinocyte formation is impaired, increased transepidermal water loss, dry skin, cracks and erosions. Changes cause imbalances in the microflora of the skin and an increase in the number of fungi, papillomas. Reconstruction of the epidermal lipid barrier in patients with metabolic syndrome is a particular challenge [7]. Table 1 - Analysis of skin epidermal lipid barrier disorders and methods for their detection. 3 Table 1 Analysis of skin epidermal lipid barrier disorders and methods for their detection Clinical manifestations of disturbances Acceleration of transepidermal water loss (caramel) and water content in the epidermal horn layer (corneometry). Skin dryness, peeling, cracks, thickening of the horn layer (hyperkeratosis). Changes in skin acid-alkali balance, pH (pH-metric sensor). Papilloma, skin infection, lipid synthesis disorders. Skin relief and morphological condition (dermatoscopy, microphotography). Skin turgor, micro-oil, papillomas, decreased elasticity, elastosis. Pigmentation and exfoliation (siascopy, mexameters). Lentigo organs and / or pigmentation heterogeneity (dispigmentation). Skin immunity (light microscopy, immunohistochemistry). Immune-competent Langerhans cells, Birbeka pellets, bacteria and / or viruses, papillomas entering the skin. Oils of different areas of the skin (sebumetry). Skin dry, oily, normal, combined. Epidermal proliferation rate (microphotography). Dimensions of comocytes, large comocytes cells in case of skin dehydration. EN 15082 Analysis of skin epidermal lipid barrier disorders is performed through dermatoscopy (skin pH, moisture / drought, grease evaluation) and siachopy (dispigmentation assessment and microrelief examination). Tewameter® TM 300, Courage + Khazaka electronic GmbH, Germany is used to measure transepidermal water loss. The Siaopolis MoleView SIAscope V Handset, Astron, United Kingdom is used to perform the Siachopia. Dermatoscope HEINE alpha + Heine Optotechnic, Germany, is used for dermatoscopy. They are used to analyze the data transmitted to the computer while performing a multi-epidermal lipid barrier characteristic analysis [8-11]: • Corneometry (skin moisture, water content in the epidermal horn layer) is used with the help of the dermatoscope. The principle of comometry is based on the measurement of the electrical capacity of the dielectric environment. Any change in the dielectric constant associated with fluctuations in water content in the upper layers of the skin results in changes in the capacitive characteristics of the measuring system. Moisture is measured on a scale. The basis is water dielectric capacity - 81, distinguishes 4-6 degrees of skin hydration (very high degree of humidity - 45.0-99.9; high, normal - 4 35.1-40.0; lowered, low-20, 1-29.9, dehydrated - below 20.0). • Measurement of transepidermal water loss, measurement of water evaporation from a skin surface based on the diffusion principle in an open chamber. The method is based on measuring partial water pressure in a closed chamber with one humidity sensor. Over time, the partial pressure increase in the chamber is measured. • Acid-base balance, pH-metric. A highly accurate glass electrode is used in the pH-meter sensor. • Sebumetria, a method of sebumetry, is used to detect skin fat in different areas. The method is based on the principle of photometry. A polymer film is used, which is a selective lipid absorbent which is placed in the photometer before and after application of the transmitter on the skin surface. Measurement results are expressed in mkg / cm. Sebumetry rates do not depend on skin moisture. The grease sensor (spongy) consists of three components, one of which is paper - matte, sensitive to fat components, which reacts only to sebum (skin fat), absorbs it, the microprocessor processes the resulting color change, determining the skin type: dry, normal, oily or combined. • Mexameters (assessment of the content of various skin pigments) allows to measure the amount of melatonin pigment in the skin and the degree of erythema. The principle of measurement is based on the fact that the skin absorbs light waves of different lengths in different spectral zones. The Mexometric method is particularly useful for quantifying allergic or inflammatory reactions caused by ultraviolet damage. • Microprint research with microphotography - use of modern digital equipment for skin surface relief and microstructure (wrinkling, smoothness, roughness) with subsequent image retention and comparison, as well as analysis of measurements during the course of treatment. Skin peeling depends mainly on the rate of epidermal proliferation as well as on the balance of the water. Normally, outgoing comocytes are about the same, small in size. The large number of large cells indicates damage to the skin and dehydration.

Zināmas kosmētiskas kompozīcijas ādas sausuma profilaksei un ārstēšanai ultravioleto (UV) bojājumu gadījumā. Zināmās kompozīcijas satur augu ekstraktus un komponentus kombinācijā ar dažādām eļļām [12-14]. Zināms, ka UV prooksidatāvo iedarbību iespējams koriģēt ar vitamīhiem-antioksidantiem [15-21]. Zināma retinoīdu lietošana UV bojājumu novēršanai [22]. Zināms krēms ar selēnmetionīnu vietējai 5 LV 15082 lietošanai insolācijas laikā, lai aizsargātos no ādas vēža [23]. Zināma mitrinošu krēmu lietošana, kuros ir liels keramīdu pārsvars, kuri paredzēti lietošanai bērniem ar atopisko dermatītu [24],Known cosmetic compositions for the prevention and treatment of skin dryness in ultraviolet (UV) lesions. Known compositions contain plant extracts and components in combination with various oils [12-14]. It is known that the effect of UV proxy can be corrected with vitamin-antioxidants [15-21]. Known use of retinoids to prevent UV damage [22]. Known cream with selenomethionine for topical 5 EN 15082 use during insolation to protect against skin cancer [23]. Known use of moisturizing creams with high ceramics predominance for children with atopic dermatitis [24],

Zināma mitrinošu līdzekļu lietošana sausas ādas ārstēšanai [25-26]. Zināma krēmu lietošana, kuros tokoferols ir kā antioksidants aizsardzībai no ādas UV bojājuma [27].Use of moisturizing agents to treat dry skin [25-26]. Known use of cream in which tocopherol is an antioxidant to protect the skin from UV damage [27].

Zināmie mitrinošie un mīkstinošie līdzekļi, kuri atvieglo ādas sausuma simptomus, ādu uzlabo mitrinot, bet neatjauno, kā ari neatrisina epidermālās lipīdu barjeras atjaunošanas problēmu pacientiem ar metabolisko sindromu.Known moisturizing and softening agents that relieve skin dryness, improve skin by moisturizing, but do not restore, as well as solve the problem of epidermal lipid restoration in patients with metabolic syndrome.

Zināms vazelīns [28], kas tiek lietots, lai īslaicīgi aizstātu bojāto ādas barjeru.Known Vaseline [28], which is used to temporarily replace the damaged skin barrier.

Vazelīns un līdzekļi, kas bāzējas uz to, tiek izmantoti pēc medicīniskām un kosmētiskām procedūrām, kurās notiek raga slāņa noņemšana, tādām kā ādas slīpēšana ar lāzeru, dermabrāzija (mehāniska epidermas noņemšana), pīlings.Vaseline and the products based on it are used for medical and cosmetic procedures in which the horn layer is removed, such as laser grinding of the skin, dermabrasion (mechanical removal of the epidermis), peeling.

Vazelīna trūkums ir slikta uzsūkšanās ādā, jo āda tiek pārklāta ar taukainu slāni, kas sarežģī tā lietošanu. Vazelīnam piemīt spēcīgs okluzīvs efekts (mitruma izgarošanas bloķēšana), kas noved pie ādas caurlaidības traucējumiem un blaknēm. Vazelīnu rekomendē lietot tikai akūta epidermālās baņeras bojājuma gadījumā, kad nepieciešams novērst īpaši aktīvu ādas šūnu reakciju, kuras pēkšņi zaudējušas ārējo aizsardzību, kā ari tajās situācijās, kad āda pati nav spējīga formēt pilnvērtīgu barjeru. Pārējos gadījumos bloķēt ūdens iztvaikošanu caur bojāto raga slāni nerekomendē.Vaseline deficiency is poor absorption in the skin as the skin is covered with a greasy layer that complicates its use. Vaseline has a strong occlusive effect (moisture vapor blocking), leading to skin permeability disorders and side effects. Vaseline is recommended to be used only in cases of acute epidermal lesion injury, when it is necessary to prevent a particularly active skin cell reaction that has suddenly lost its external protection, as well as in situations where the skin itself is unable to form a complete barrier. In other cases blocking water evaporation through the damaged horn layer is not recommended.

Zināma tauku emulsija, ar kuru vienlaikus iespējama ādas mitrināšana un barošana [29]. Zināmā tauku emulsija neveic aizsargājošu iedarbību pret ādas novecošanās procesiem, kurus izraisījuši ādas brivo radikāļu bojājumi pacientiem ar metabolisko sindromu.A known fat emulsion that can simultaneously moisturize and nourish the skin [29]. A known fat emulsion does not have a protective effect on skin aging processes caused by lesions of the skin's radicals in patients with metabolic syndrome.

Zināms krēms ar selēnu un E vitamīnu [30], kas ir augsti dispersa rafinētas ūdeles eļļas emulsija ūdenī stabilizēta ar emulsijas vaskiem. Krēms nenovērš lipīdu barjeras atjaunošanu pacientiem ar metabolisko sindromu. Turklāt, ilgstoši lietojot krēmu ar augstu ūdens saturu, palēninās raga slāņa atjaunošanās, kas nelabvēlīgi ietekmē ādu pacientiem ar metabolisko sindromu [31]. Zināmas dažādas kompozīcijas no augu ekstraktiem ādas barjerās funkcijas stāvokļa uzlabošanai [32-36]. Zināmās kompozīcijas neatjauno lipīdo slāni pacientiem ar metabolisko sindromu.Known cream with selenium and vitamin E [30], a highly dispersed refined mink oil emulsion in water stabilized with emulsion waxes. The cream does not prevent the lipid barrier being restored in patients with metabolic syndrome. In addition, prolonged use of high-water cream slows down the recovery of the horn layer, which has an adverse effect on the skin in patients with metabolic syndrome [31]. Known different compositions from plant extracts to improve the function of the skin barrier [32-36]. Known compositions do not restore the lipid layer in patients with metabolic syndrome.

Nav zināms līdzeklis epidermālās lipīdu barjeras atjaunošanai pacientiem ar metabolisko sindromu. 6No remedy for the restoration of the epidermal lipid barrier in patients with metabolic syndrome is known. 6

IZGUDROJUMA IZKLĀSTSDESCRIPTION OF THE INVENTION

Izgudrojuma mērķis un tehniskais rczulāts: izstrādāt krēma sastāvu sejas ādas, kakla un dekoltē zonas epidermālās lipīdu barjeras atjaunošanai pacientiem ar metabolisko sindromu, kas novērstu brīvo radikāļu radīto bojājumu lipīdu slānim, kuru izraisījis latents iekaisums, piemītošs metaboliskajam sindromam, un atjaunotu lipīdu slāni: • jaunā sastāva komponentu un to sastarpējās attiecības meklēšana, • krēma izgatavošanas tehnoloģijas izstrādāšana, • krēma optimālās formas izstrādāšana.Purpose and Technical Purpose of the Invention: Develop a cream composition for regeneration of the epidermal lipid barrier in the facial skin, neck and décolleté area in patients with metabolic syndrome that would prevent the free radical damage to the lipid layer caused by latent inflammation inherent in metabolic syndrome and restore the lipid layer: • new search for composition components and their interrelation, • development of cream making technology, • development of optimal cream form.

Izvirzīto mērķi sasniedz tādējādi, ka krēms satur selēn-L-metionīnu, α-tokoferola acetātu, skvalānu, metil-4— hidroksibenzoātu, glicerīna monostearātu 60, cetilspirtu, vidēji garo ķēžu trigliceiīdus, balto vazelīnu, makrogola-20-glicerīna monostearātu, 1,2-propāndiolu un attīrītu ūdeni. Pie tam krēms satur selēn-L-metionīnu, α-tokoferola acetātu, skvalānu, metil-4-hidroksibenzoātu, glicerīna monostearātu 60, cetilspirtu, vidēji garo ķēžu triglicerīdus, balto vazelīnu, makrogola-20-glicerīna monostearātu, 1,2-propāndiolu un attīrītu ūdeni šādās komponentu masas attiecībās g (%): selēn-L-metionīns 0,0005-0,0015; α-tokoferola acetāts 0,50-1,50; skvalāns 11,25-18,75; metil-4- hidroksibenzoāts 0,05-0,15; glicerīna monostearāts 60 2,52-4,20; cetilspirts 3,78-6,29; vidēji garo ķēžu triglicerīdi 4,72-7,87; baltais vazelīns 16,05-26,74; makrogols-20-glicerīna monostearāts 4,40-7,34; 1,2-propāndiols 6,29-10,49; attīrīts ūdens līdz 100,0. Krēma sastāvs ir homogēna masa balta krāsa vai balta krasā ar dzeltenīgu nokrāsu, vāji izteiktu un patīkamu aromātu, atbilstošu lietotajai tauku bāzei. Visi krēma komponenti atļauti lietošanai par farmaceitiskiem līdzekļiem.The goal is achieved by the fact that the cream contains selenium-L-methionine, α-tocopherol acetate, squalane, methyl-4-hydroxybenzoate, glycerol monostearate 60, cetyl alcohol, medium chain triglycerides, white petroleum jelly, macrogol-20-glycerol monostearate, 1, 2-propanediol and purified water. In addition, the cream contains selenium-L-methionine, α-tocopherol acetate, squalane, methyl-4-hydroxybenzoate, glycerol monostearate 60, cetyl alcohol, medium chain triglycerides, white petroleum jelly, macrogol-20-glycerin monostearate, 1,2-propanediol and purified water in the following component weight ratios g (%): selenium-L-methionine 0.0005-0.0015; α-tocopherol acetate 0.50-1.50; squalane 11,25-18,75; methyl 4-hydroxybenzoate 0.05-0.15; glycerol monostearate 60 2.52-4.20; cetyl alcohol 3.78-6.29; medium chain triglycerides 4.72-7.87; White Vaseline 16.05-26.74; macrogol-20-glycerol monostearate 4.40-7.34; 1,2-propanediol 6.29-10.49; purified water to 100.0. The cream composition is a homogeneous mass of white or white in color with a yellowish tinge, a weak and pleasant aroma, consistent with the fat base used. All cream components are authorized for pharmaceutical use.

Krēms paredzēts sejas ādas, kakla un dekoltē zonas epidermālās lipīdu barjeras atjaunošanai pacientiem ar metabolisko sindromu. 7 LV 15082The cream is designed to rejuvenate the epidermal lipid barrier of the face, neck and décolleté patients with metabolic syndrome. 7 LV 15082

Krēma sastāvs satur šādus komponentus:The composition of the cream contains the following components:

Selēn-L-metionīns (Selenomethionine, Se-Met (SEM)) - selēnmetionīna L-enantiomērs, dabīga selēnu saturoša aminoskābe, tā ir nozīmīgs selēna avots.Selenomethionine (Se-Met (SEM)) - L-enantiomer of selenomethionine, a natural selenium-containing amino acid, is an important source of selenium.

Selēnmetionīns veic bioantioksidata funkciju, mijiedarbojas ar vitamīniem, fermentiem, bioloģiskajām membrānām bioloģiskajās sistēmās un organismā kopumā.Selenium methionine performs a bioanthoxidate function, interacts with vitamins, enzymes, biological membranes in biological systems and the body as a whole.

Fermenta sastāvā glutationperoksidāzes neitralizē oksīdus un peroksīdus, pasargā šūnu membrānas no sabrukšanas, veic antihistamīnu iedarbību, stimulē kolagēna, keratīna biosintēzi, piedodot ādai stingrumu un elastību, samazina seborejas izpausmes, aktivizē ādas reģeneratīvos procesus, atjauno epidermas struktūru.Glutathione peroxidase neutralizes oxides and peroxides in enzyme composition, protects cell membranes from collapse, exerts antihistamines, stimulates collagen, keratin biosynthesis, gives skin firmness and elasticity, reduces seborrhea, activates skin regenerative processes, restores skin regenerative processes, restores epidermal structure, restores epidermal structure.

Neorganisko selēnu, selēna disulfīdu (Selenium disulfide) lieto galvas ādas matu zonas seborejas ārstēšanai [37]. Pēc ASV pieņemta standarta drošs selēna saturs (no intoksikācijas viedokļa) pieauguša cilvēka ikdienā uzņemamajā uzturā ir 50-220 mkg, saskaņā ar Ķīnā veiktajiem pētījumien toksiskas izpausmes netika novērotas, uzņemot diennaktī 750 mkg selēna, bet intoksikācijas simptomi novērojami, ja diennakts devu palielina līdz 5000 mkg/diena [38],Inorganic selenium, selenium disulfide (Selenium disulfide) is used to treat scalp hair zones in seborrhea [37]. In the US, the standard safe selenium content (from the point of view of intoxication) is 50-220 mcg in the daily diet of an adult, according to studies conducted in China, there was no evidence of daily exposure to 750 mcg of selenium, while symptoms of intoxication were observed when the daily dose was increased to 5,000. mkg / day [38]

Selēnmetionīns ir hidrofila viela, optimālais selēnmetionīna satura efekts krēma sastāvā 0,0005-0,0015 g. Ja tā saturs mazāks par 0,0005 g, tad krēma antioksidatīvā iedarbība samazinājās, bet, ja tā saturs lielāks par 0,0015 g, tad radās grūtības krēma izgatavošanā, izmainījās krēma konsistence, tas noslāņojās, nebija tik viendabīgs, tas apgrūtināja krēma lietošanu.Selenium methionine is a hydrophilic substance, the optimum effect of selenium methionine in the cream composition is 0.0005-0.0015 g. If its content is less than 0.0005 g, the antioxidant effect of the cream was reduced, but if its content was higher than 0.0015 g, the cream was difficult to make, the consistency of the cream changed, it was stratified, it was not homogeneous, it made it difficult to use the cream.

Skvalāns (Squalane) - karotinoīdu grupas dabiskas izcelsmes ogļūdeņradis, caurspīdīga eļļa bez krāsas un aromāta. Skvalāns nesatur dubultsaites, tāpēc tas ir ķīmiski stabils un var uzglabāties vairāk par 2 gadiem, tas neoksidējas un nekļūst rūgtens. Skvalāns sintezējas tauku dziedzeros, tas ir viens no ādas tauku un ūdens-lipīdu mantijas galvenajiem komponentiem. Saskaņā ar dermatokosmetoloģiju skvalans ir augsti kvalitatīvs emolents (mīkstināšanas aģents). Skvalāns ir nekomedogēns, atšķirībā no triglicerīdiem un ādas tauku slāņa taukskābēm [39-dOJ.Squalane - a naturally occurring hydrocarbon of the carotenoid group, a clear oil free of color and aroma. Squalane does not contain double bonds, so it is chemically stable and can be stored for more than 2 years, it does not oxidize and does not become bitter. Squalane synthesizes in sebaceous glands, one of the main components of skin fat and water-lipid mantle. According to dermatocosmetology, squalene is a high quality emollient (softening agent). Squalane is non-comedogenic, unlike triglycerides and fatty acids in the skin [39-dOJ.

Skvalānu uzklājot uz ādas, tas viegli ieziešas, veidojot aizsargājošu plēvi, kas pasargā no mitruma zuduma, uzlabo ādas elpošanu. Pateicoties dabiskajai radniecībai ar ādu, skvalāns viegli izsūcas cauri epideimai, neatstājot nekādu taukainību, vienlaicīgi ādu padara maigu un zīdainu. Skvalāns ir hidrofoba viela, tas aktīvi iesaistās vielmaiņā, steroīdu bioloģiskajā sintēzē, tam piemīt viegls antibakterials efekts, tas palīdz novērst vecuma plankumu rašanos. Optimālais skvalāna satura efekts krēma sastāvā 11,25—18,75 g. Ja tā saturs mazāks par 11,25 g, tad ādas struktūras mīkstināšanas un 8 atjaunošanas efekts ievērojami samazinājās, bet, ja tā saturs lielāks par 18,75 g, tad. radās grūtības krēma izgatavošanā, samazinājās kompozīcijas stabilitāte, krēms noslāņojās, tika apgrūtināta tā lietošana. E vitamīns, a-tokoferols (Vitamin E, Alpha-tocopherol) - gaiši dzeltens, caurspīdīgs, viskozs šķidrums ar vāju aromātu. Gaismā oksidējas un kļūst tumšs. Tokoferols ir hidrofoba viela, to satur jauno augu zaļās daļas, augu eļļas, tas ir dabiskais antioksidants, kas piedalās brīvo radikāļu inaktivācijā, pasargā šūnu membrānas no sabrukuma, tajā skaitā, arī ultravioletā starojuma gadījumā, piedalās olbaltumvielu sintēzē, samazina seborejas izpausmes, aktivē ādas reģeneratīvos preocesus [41]. E vitamīna iekļaušana krēma sastāvā ļāva sasniegt daudz ātrāku ādas epidermālās lipīdu barjeras atjaunošanu pacientiem ar metabolisko sindromu. Optimālais α-tokoferola (E vitamīna) satura efekts krēma sastāvā 0,50-1,50 g. Ja tā saturs mazāks par 0,50 g, tad efekts ievērojami samazinājās, bet, ja tā saturs lielāks par 1,50 g, tad izmainījās krēma konsistence, tas kļuva ievērojami šķidrāks, tika apgrūtināta tā lietošana.Applying the scalp to the skin, it gently lubricates to form a protective film that protects against moisture loss, improves skin breathing. Thanks to the natural skin contact, squalane easily penetrates through the epidemic, leaving no grease, making the skin soft and silky at the same time. Squalane is a hydrophobic substance that actively engages in metabolism, biological synthesis of steroids, has a mild antibacterial effect and helps prevent age spots. Optimal effect of squalane content in cream composition 11.25-18.75 g. If its content is less than 11.25 g, the effect of softening of the skin structure and 8 regeneration significantly decreased, but if its content is greater than 18.75 g then. there was a problem in the production of the cream, the stability of the composition was reduced, the cream layered and its use was difficult. Vitamin E, α-tocopherol (Vitamin E, Alpha-tocopherol) - light yellow, translucent, viscous liquid with a weak aroma. Light oxidizes and becomes dark. Tocopherol is a hydrophobic substance, it contains the green parts of new plants, vegetable oils, it is a natural antioxidant that participates in inactivation of free radicals, protects cell membranes from collapse, including in the case of ultraviolet radiation, participates in protein synthesis, reduces seborrhea, activates seborrhoea, activates skin \ t regenerative preocesses [41]. The inclusion of Vitamin E in the cream formulation has led to a much faster rejuvenation of the epidermal lipid barrier in patients with metabolic syndrome. Optimal effect of α-tocopherol (vitamin E) content in cream composition 0.50-1.50 g. If its content was less than 0.50 g, the effect was greatly reduced, but if its content was higher than 1.50 g, the consistency of the cream changed, it became considerably more liquid, and difficult to use.

Metil-4-hidroksibenzoāts (Methyl paraben), CH3(C6H4(OH)COO) - baltas krāsas vai krēmkrāsas kristālisks pulveris, kas slikti šķīst ūdenī. Tas šķīst siltā ūdenī, metanolā, propilēnglikolā. To raksturo plašs antibakteriālās un pretsēnīšu iedarbības spektrs, tas dabiskā veidā sintezējas dažos augos, piemēram, mellenēs. To lieto pret pelējuma un gramnegatīvām baktērijām [42]. Cilvēka organismā viegli un pilnīgi uzsūcas caur ādu vai caur kuņģa-zamu traktu, sadalās vienkāršākās vielās un ātri tiek izvadīts ar urīnu, neuzkrājoties organismā. To izmanto par stabilizatoru un/vai prolongatoru, efektīvs ļoti zemās koncentrācijas, tīrā veidā un 0,25 %-5 % spirta šķīduma veidā. Optimālais metil-4-hidroksibenzoāta satura efekts krēma sastāvā 0,05-0,15 g. Ja tā saturs mazāks par 0,05 g, tad stabilizatora efekts ievērojami samazinājās, bet, ja tā saturs lielāks par 0,15 g, tad izmainījās krēma konsistence, bija manāmi neizšķīdušie ieslēgumi, tika apgrūtināta krēma lietošana.Methyl 4-hydroxybenzoate (Methyl paraben), CH3 (C6H4 (OH) COO) - a white or cream-colored crystalline powder which is poorly soluble in water. It is soluble in warm water, methanol, propylene glycol. It is characterized by a broad spectrum of antibacterial and antifungal activity, which naturally synthesizes in some plants, such as blueberries. It is used against mold and gram-negative bacteria [42]. The human body is easily and completely absorbed through the skin or through the gastrointestinal tract, decomposes into simpler substances and is rapidly excreted in the urine without accumulation in the body. It is used as a stabilizer and / or prolonger, effective in the form of a very low concentration, pure and 0.25% -5% alcohol solution. The optimum effect of the methyl 4-hydroxybenzoate content in the cream composition is 0.05 to 0.15 g. If its content is less than 0.05 g, the stabilizer effect was significantly reduced, but if its content was higher than 0.15 g, the consistency of the cream changed, the insoluble inclusions were noticeable, the use of the cream was difficult.

Glicerīna monostearāts 60 (Glycery Stearaie) - baltas krāsas pulveris, kas iegūts no dabiskās stearīnskābes un glicerīna, ar perlamutra efektu (atstaro gaismu), ir vaskveidīgs, ciets emolents, emulgators un biezinātājs, to pievieno samaisīšanas fāzes stabilizācijas procesā. Tiek lietots kā stabilizējošs un strukturizējošs komponents, lai novērstu sastāva (kompozīcijas) hidrofobās un hidrofilās fāzes atdalīšanu, nosēdumu atdalīšanu [43]. Ja tā saturs mazāks par 2,52 g, tad biezinātāja efekts ievērojami 9 9LV 15082 samazinājās, bet, ja tā saturs lielāks par 4,20 g, tad izmainījās krēma konsistence, krēms kļuva ļoti biezs, tika apgrūtināta krēma lietošana.Glycerine Monostearate 60 (Glycery Stearaie) - a white powder obtained from natural stearic acid and glycerin, with a pearl effect (reflecting light), is a waxy, solid emolent, emulsifier and thickener, added to the mixing phase stabilization process. Used as a stabilizing and structuring component to prevent separation of the hydrophobic and hydrophilic phases of the composition (composition), removal of sediment [43]. If its content was less than 2.52 g, the thickening effect was significantly reduced to 9 9LV 15082, but if its content was higher than 4.20 g, the consistency of the cream changed, the cream became very thick, the use of the cream was difficult.

Cetilspirts (Cetyl alcohol, l-hexadecanoI), CH3(CH2)i4CH20H, vienatoma taukains spirts, cieta baltas krāsas viela, tauku bāzes sastāvā tiek lietots par emulgatoru un/vai saduļkotāju (opacifier), kas uzlabo konsistenci, paaugstina ūdens-eļļas maisījuma stabilitāti [44]. Lietošanai rekomendējamie grami: 3,78-6,29 g. Ja tā saturs mazāks par 3,78 g, tad emulgatora efekts ievērojami samazinājās, krēms noslāņojās, bet, ja tā saturs lielāks par 6,29 g, tad mainījās krēma konsistence, krēms kļuva pārāk šķidrs, tika apgrūtināta krēma lietošana.Cetyl alcohol (1-hexadecanoI), CH3 (CH2) i4CH2OH, mono-fatty alcohol, solid white color, used as a fat-based emulsifier and / or opacifier, which improves consistency, increases the stability of the water-oil mixture [44]. Recommended grams for use: 3.78-6.29 g. If its content is less than 3.78 g, the emulsifier effect decreased significantly, the cream layered, but if its content was greater than 6.29 g, the consistency of the cream changed, the cream became too liquid, the use of the cream was difficult.

Vidēji garo ķēžu triglicerīdi (Triglycerides medium-cham) - eļļains šķīdums, kas iegūts no kokoseļļas, nesšķīstošs ūdenī, sajaucams ar eļļām [45], Uzlabo krēma izvietojuma vienmērību uz ādas, izšķīdina lipofīlos savienojumus. Lietošanai rekomendējamie grami: 4,72-7,87 g. Ja tā saturs mazāks par 4,72 g, tad stabilizatora efekts ievērojami samazinājās, krēms noslāņojās, bet, ja tā saturs lielāks par 7,87 g, tad mainījās krēma konsistence, krēms kļuva pārāk šķidrs, tas apgrūtināja krēma lietošanu.Triglycerides medium-cham - an oily solution derived from coconut oil, insoluble in water, miscible with oils [45], Improves the smoothness of cream placement on the skin, dissolves lipophilic compounds. Recommended grams for use: 4.72-7.87 g. If its content is less than 4.72 g, the stabilizer effect decreased significantly, the cream layered, but if its content was higher than 7.87 g, the consistency of the cream changed, the cream became too liquid, which made it difficult to use the cream.

Baltais vazelīns (Vaselinum) - cietu un mīkstu augstmolekulāru ogļūdeņražu maisījums, kas iegūts, samaisot balto cerezīnu un parafīnu ar parfimērijas eļļu [46]. Vazelīnu lieto kā biezinātāju ādas krēmu un ziežu sastāvā. To lietojot ārēji, vazelīns sekmē ādas ūdens—lipīdu aizsargmantijas atjaunošanos, novērš šķidruma zudumu ādas šūnās, novērš ādas lobīšanos un plaisas. Vazelīns paredzēts sejas un roku ādas mīkstināšanai, tajā skaitā, ārējās vides negatīvo faktoru ietekmes izraisītajos gadījumos (saule, vējš, temperatūras izmaiņas). Ja tā saturs mazāks par 16,05 g, tad biezinātāja efekts ievērojami samazinājās, bet, ja tā saturs lielāks par 26,74 g, tad mainījās krēma konsistence, krēms kļuva pārāk biezs, tas apgrūtināja krēma lietošanu.White Vaseline (Vaselinum) is a blend of hard and soft high molecular hydrocarbons obtained by mixing white ceresin and paraffin with perfume oil [46]. Vaseline is used as a thickener in skin cream and ointment. When used externally, Vaseline contributes to the rejuvenation of the skin's water-lipid protector, eliminates fluid loss in the skin cells, prevents skin peeling and cracks. Vaseline is designed to soften the skin of the face and hands, including in cases caused by the effects of external environmental factors (sun, wind, temperature changes). If its content is less than 16.05 g, the thickening effect was greatly reduced, but if its content was higher than 26.74 g, the consistency of the cream changed, the cream became too thick, which made it difficult to use the cream.

Makrogols-20-glicerma monostearāts (Macrogol), struktūrfonnula H0-(CH2-CH2-0)n-H, balts pulveris, veido ūdeņraža saites ar ūdens molekulām, to lieto medicīnā un kosmētikā kā savienojošo komponentu, izgatavojot bāzi ziedēm, to lieto arī kā stabilizējošo un strukturizējošo komponentu, kas padara sastāvu vienmērīgu [47]. Makrogola augstā hidrofilā pakāpe ļauj visefektīvāk veikt kompozīcijas homogenizāciju daudzumā 4,40-7,34 g, emulģējot jaunā krēma hidrofobos komponentus. Ja tā saturs mazāks par 4,40 g, tad biezinātāja efekts ievērojami samazinājās, bet, ja tā saturs lielāks par 7,34 g, tad mainījās krēma konsistence, krēms kļuva pārāk biezs, tas apgrūtināja krēma lietošanu. 10 1,2-propāndioIs (l,2-propylenglycol), CH3CH(0H)CH20H, organiska viela, bezkrāsains, viskozs hidroskopisks šķidrums, bez aromāta, mitrumu uzturēšanas, mīkstināšanas un disperģēšanas aģents, labs šķīdinātājs [48]. Ar to pilnīgi sajaucas vairums mazmolekulāru organisku savienojumu, saturošu skābekli un slāpekli. Ja tā saturs mazāks par 6,29 g, tad biezinātāja efekts ievērojami samazinājās, bet, ja tā saturs lielāks par 10,49 g, tad mainījās krēma konsistence, tas kļuva pārāk biezs un tika apgrūtināta krēma lietošana. Ūdens (Aqua) bāzes sastāvā ietilpst kā emulsijas „ūdens eļļā” daļa (kur ūdens - emulsijas hidrofilā daļa, eļļa un skvalēns - hidrofobā daļa). Lietošanai rekomendējamais daudzums: līdz 100 g. Ja tā saturs mazāks par 33,0 g, tad biezinātāja efekts ievērojami samazinājās, bet, ja tā saturs lielāks par 34,6 g, tad mainījās krēma konsistence, tas kļuva pārāk biezs, tika apgrūtināta krēma lietošana.Macrogol-20-glycerol monostearate (Macrogol), structural pellet H0- (CH2-CH2-0) nH, white powder, forms hydrogen bonds with water molecules, is used in medicine and cosmetics as a connecting component for making base for ointments, it is also used as a stabilizing agent and a structuring component that makes the composition smooth [47]. The high hydrophilic degree of macrogol allows the homogenization of the composition to be most efficient in an amount of 4.40-7.34 g, emulsifying the hydrophobic components of the new cream. If its content is less than 4.40 g, the thickening effect was greatly reduced, but if its content was higher than 7.34 g, the consistency of the cream changed, the cream became too thick, which made it difficult to use the cream. 10 1,2-Propanediol (1,2-propylenglycol), CH3CH (0H) CH2OH, organic matter, colorless, viscous hydroscopic liquid, odorless, moisture retaining, softening and dispersing agent, good solvent [48]. It completely blends most of the small molecular organic compounds containing oxygen and nitrogen. If its content is less than 6.29 g, the thickening effect was significantly reduced, but if its content was greater than 10.49 g, the consistency of the cream changed, becoming too thick and difficult to use. The water (Aqua) base contains as part of the water-in-oil emulsion (the hydrophilic part of the emulsion, the oil and the squalene - the hydrophobic part). Recommended use: up to 100 g. If its content is less than 33.0 g, the thickening effect was significantly reduced, but if its content exceeded 34.6 g, the consistency of the cream changed, it became too thick, the use of the cream was difficult.

Jaunais krēma sastāvs tika sekmīgi lietots, iegūstot dozētu formu tūbās pa 65,0 g (pa 30,0 g). Visi jaunā krēma sastāva komponenti, kā atsevišķi preparāti, atļauti lietošanai dermatoloģijā izgudrojumā minēto attiecību robežās. Jaunā krēma sastāvs un izgatavošanas tehnoloģija atbilst produktu drošības novērtējuma standarta kritērijiem saskaņā ar Eiropas Komisijas prasībām (Parlamenta un Padomes regula (EK) Nr.1223/2009 (2009. gada 30. novembris) par kosmētikas līdzekļiem, 11. pants). I.- Π. Krēma sastava piemēriThe new cream composition was successfully used to obtain a dosage form of 65.0 g (30.0 g) in tubes. All components of the new cream composition, as separate preparations, are permitted for use in dermatology within the scope of the invention. The composition and manufacturing technology of the new cream complies with the standard criteria for product safety assessment in accordance with European Commission requirements (Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic products, Article 11). I.- Π. Examples of cream composition

Sastāvs satur: selēn-L-metionīns 0,0005-0,0015; α-tokoferola acetāts 0,50-1,50; skvalāns 11,25-18,75; metil-4- hidroksibenzoāts 0,05-0,15; glicerīna monostearāts 60 2,52-4,20; cetilspirts 3,78-6,29; vidēji garo ķēžu triglicendi 4,72-7,87; baltais vazelīns 16,05-26,74; makrogols-20-gliceriha monostearāts 4,40-7,34; 1,2-propāndiols 6,29-10,49; attīrīts ūdens līdz 100,0. 11 11LV 15082The composition contains: selenium-L-methionine 0.0005-0.0015; α-tocopherol acetate 0.50-1.50; squalane 11,25-18,75; methyl 4-hydroxybenzoate 0.05-0.15; glycerol monostearate 60 2.52-4.20; cetyl alcohol 3.78-6.29; medium length triglyceride 4.72-7.87; White Vaseline 16.05-26.74; macrogol-20-glycerol monostearate 4.40-7.34; 1,2-propanediol 6.29-10.49; purified water to 100.0. 11 11LV 15082

Krēma iegūšanas paņēmiensCream extraction technique

Jaunā krēma sastāva izgatavošanas sarežģītība saistīta ar to, ka skvalāns, glicerīns, triglicerīdi, vazelīns un α-tokoferols ir hidrofobas vielas, bet selēnmetionīns, makrogols, propāndiols - hidrofilas vielas.The complexity of making the new cream composition is due to the fact that squalane, glycerin, triglycerides, vaseline and α-tocopherol are hydrophobic substances, and selenomethionine, macrogol, propanediol - hydrophilic substances.

Pirmā krēma sastāva iegūšanas paņēmiens 1. Krēma hidrofobās daļas pagatavošana.Method of obtaining the first cream composition 1. Preparation of the hydrophobic part of the cream.

Krēma pagatavošanas traukā ūdens vannā 65-70 °C temperatūrā izkausē 2,52-4,20 g glicerīna monostearāta 60 un 3,78-6,29 g cetilspirta, pievieno un izkausē 16,05-26,74 g vazelīna, pievieno 11,25-18,75 g skvalāna un 4,72-7,87 g vidēji garo ķēžu triglicerīdus, maisa līdz viendabīgumam. Sakausējuma temperatūrai jābūt 60 °C. 2. Krēma hidrofilās daļas pagatavošana.Cream 2.52-4.20 g of glycerol monostearate 60 and 3.78-6.29 g of cetyl alcohol in a water bath at 65-70 ° C in a water bath, add and melt 16.05-26.74 g of Vaseline, add 11, 25-18.75 g of squalane and 4.72-7.87 g of medium chain triglycerides are stirred to homogeneity. The alloy temperature must be 60 ° C. 2. Preparation of the hydrophilic part of the cream.

Stikla vārglāzē 6,29-10,49 g 1,2-propāndiola 45-50 °C temperatūrā izšķīdina 0,05-0,15 g metil-4-hidroksibenzoāta, pievieno daļu no atlikušā attīrīta ūdens, samaisa, pievieno 4,40-7,34 g makrogola-20-gliceiīna monostearāta, izšķīdina, sildot līdz 60 °C temperatūrai. 3. Krēma pagatavošanas traukā pie hidrofobās daļas pievieno hidrofilo daļu, maisa krēma maisīšanas iekārtā 15-20 minūtes, kamēr masa atdziest līdz 30-35 °C temperatūrai. 4. Krēma masai pievieno 0,50-1,50 g α-tokoferola acetāta un 0,0005-0,0015 g selēn-L-metionīna, kas izšķīdināts daļā no atlikušā attīrītā ūdens. Maisa krēma maisīšanas iekārtā 10 minūtes līdz viendabīgas masas iegūšanai.In a glass beaker, 6.29 to 10.49 g of 1,2-propanediol are dissolved at 0.05 to 0.15 g of methyl 4-hydroxybenzoate at 45-50 ° C, part of the residual purified water is added, stirred, 4.40- 7.34 g of macrogol-20-glycerine monostearate, dissolved by heating to 60 ° C. 3. Add a hydrophilic portion to the hydrophobic portion of the cream preparation vessel, stir the cream in the mixing machine for 15-20 minutes until the mass cools to 30-35 ° C. 4. Add 0.50 to 1.50 g of α-tocopherol acetate and 0.0005-0.0015 g of selenium-L-methionine dissolved in a portion of the remaining purified water to the cream mass. Stir the cream in the mixing machine for 10 minutes to obtain a homogeneous mass.

Otrā sastāva iegūšanas paņēmiens - analoģisks pirmajam. Iegūto krēmu fasē alumīnija tūbās pa 65,0 g (pa 30,0 g).The method of obtaining the second composition is analogous to the first one. The resulting cream is packed in aluminum tubes of 65.0 g (30.0 g).

Krēma sastāvs ir homogēna masa baltā krāsā vai baltā krāsā ar dzeltenīgu nokrāsu, vāji izteiktu un patīkamu aromātu, atbilstošu lietotajai tauku bāzei.The cream is homogenous in white or white with a yellowish tinge, a weak and pleasant aroma, suitable for the fat base used.

Krēms paredzēts sejas ādas, kakla un dekoltē zonas epidermālās lipīdu barjeras atjaunošanai pacientiem ar metabolisko sindromu. Krēmam piemīt komponentu biosaderiba, tas viegli iesūcas ādā, to pārklājot ar plānu, elastīgu slāni, krēma pH 4,0-5,0. Krēmam piemīt ādu nomierinoša iedarbība, tas mazina niezi un iekaisumu, to ilgstoši lietojot, tas neizraisa kairinājumus un blaknes.The cream is designed to rejuvenate the epidermal lipid barrier of the face, neck and décolleté patients with metabolic syndrome. The cream has a component biocompatibility, it is easily absorbed into the skin, covered with a thin, supple layer, the cream pH 4.0-5.0. The cream has a soothing effect on the skin, it relieves itching and inflammation by prolonged use, it does not cause irritation and side effects.

Lai novērtētu krēma īpašības, saistībā ar ādas epidermālās lipīdu barjeras profilaksi un/vai atjaunošanu, izmantojot „LIPEX” (Rīga) dermatoloģijas klīnikas un 12 estētiskās medicīnas bāzi, tika veikts prospektīvs klīnisks pētījums, kura ietvaros informatīvas, brīvprātīgas piekrišanas apstākļos tika aicināti vīrieši un sievietes ar metabolisko sindromu vecumā 39-55 gadi. Rezultātā tika atlasītas 2 vienveidīgas pacientu grupas ar metabolisko sindromu, kuri nesmēķē, neapmeklē solāriju, ar vidēju insolācijas pakāpi (vidēja saules ekspozīcija, visu sezonu pavada Vidus- un Ziemeļeiropas apstākļos). Pirmās grupas (1. grupa, n=12) un otrās grupas (2. grupa, n=15) sastāvā iekļauti pacienti, kuriem diagnosticēts metaboliskais sindroms. Metaboliskā sindroma diagnoze tika noteikta, pamatojoties uz izmaiņu kompleksu, saskaņā ar Starptautisko slimību klasifikatoru (10. izdevums) [1] un ASV Nacionālā veselības aizsardzības institūta speciālistu veikto analīzi: metaboliskais sindroms tika noteikts pēc trijiem vai vairākiem simptomiem: • aptaukošanās abdominālais tips - vidukļa apkārtmēra rādītājs lielāks par 89 cm sievietēm un lielāks par 102 cm vīriešiem, • glikozes līmenis tukšā dūšā - lielāks par 6,1 mmol/1, • triglicerīdu līmenis - lielāks par 1,69 mmol/1, • zema blīvuma lipoproteīnu līmeņa pazemināšanās: sievietēm - mazāks par 1,29 mmol/1; vīriešiem - mazāks par 1,04 mmol/1, • arteriālā asinsspiediena līmenis 135/85 mmHg. Pētījuma protokols, vienošanās un dalības protokols, dalības anketa atbilst Pasaules Medicīnas asociācijas (PMA) Helsinku deklarācijas ētiskajiem un humānisma principiem medicīnā, kā an apstiprināti Rīgas Stradiņa universitātes Ētikas komisijā. Interešu konflikts nepastāv. 1. grupas pacientiem (n=12), pēc iepriekšējas klīniskās izmeklēšanas, krēms tika nozīmēts ilgstoši (2 mēnešus, aktīvas UV insolācijas laikā, maija un jūnija mēnešos). Krēmu uzklāja plānā kārtiņā, 2 reizes dienā (rītā un vakarā) uz tīras sejas ādas, kakla un dekoltē zonas. 2. grupas pacienti krēmu nelietoja. Abās grupās klīniskos pētījumus atkārtoja pēc 14, 30 un 60 dienām, sākot no krēma lietošanas sākuma.In order to evaluate the properties of the cream, in connection with the prevention and / or restoration of the epidermal lipid barrier of the skin using the LIPEX (Riga) dermatology clinic and 12 aesthetic medicine base, a prospective clinical study was conducted in which men and women were invited under informative, voluntary consent. with metabolic syndrome aged 39-55 years. As a result, 2 homogeneous groups of patients with non-smoking metabolic syndrome were selected, did not go to the solarium, with a moderate degree of insolation (medium exposure, spent all season in Central and North Europe). The first group (Group 1, n = 12) and the second group (Group 2, n = 15) include patients diagnosed with metabolic syndrome. The diagnosis of metabolic syndrome was based on a complex of changes, according to an analysis by the International Classification of Diseases (10th edition) [1] and the US National Institute of Health: metabolic syndrome was identified by three or more symptoms: • abdominal type of obesity - waist circumference greater than 89 cm for women and over 102 cm for men, • fasting glucose - greater than 6.1 mmol / l, - triglycerides higher than 1.69 mmol / 1, - low density lipoproteins: women less than 1.29 mmol / l; for men - less than 1.04 mmol / l, • arterial blood pressure level of 135/85 mmHg. The protocol of the study, the agreement and the protocol of participation, the participation questionnaire correspond to the ethical and humanist principles of medicine in the World Medical Association (PMA) Helsinki Declaration, as approved by the Riga Stradins University Ethics Commission. There is no conflict of interest. In group 1 patients (n = 12), after a previous clinical trial, the cream was prescribed for a long time (2 months, during active UV insolation, in May and June). The cream was applied in a thin layer twice a day (morning and evening) on a clean face skin, neck and décolleté area. Group 2 patients did not use the cream. In both groups, clinical trials were repeated after 14, 30 and 60 days from the start of the cream application.

Klīniskie pētījumi ietvēra antropometriskos datus (ķermeņa masas indekss, vidukļa apkārtmērs, arteriālais asinsspiediens), asins analīzi (glikoze, lipoproteīni). Lai novērtētu ādas epidermālo lipīdu barjeru, veica siaskopiju un dermatoskopiju (siaskops MoleVievv SIAscope V Handset, Astron, Lielbritānija un dermatoskops HEINE alpha + Heine Optotechnic, Vācija). Ādas reljefa un morfoloģijas stāvoli (turgors, mikroreljefs un papilomu esamība) novērtēja ar dermatoskopijas 13 13LV 15082 starpniecību. Pigmentāciju un lobīšanos novērtēja, izmantojot siaskopiju. plī-metrijas mērījumus veica ar pH-metrijas sensora palīdzību. Transepidermālā ūdens zuduma mērījumus veica ar sensora Tewameter® TM 300, Courage + Khazaka eleclronic GmbH, Vācija, (tevametrija) palīdzību. Ar šiem sensoriem iegūtu pētījuma rezultātu aprēķinu un saglabāšanu veica, izmantojot programmnodrošinājumu datu bāzē SPSS 20,0 {Microsoft, ASV). Rezultātus reģistrēja skaitliskās vērtībās. Korneometrijas rādītāju normālo vērtību robežas bija no 40 un augstākas, tevametrijas - zemākas par 12, pH-metrija.s - robežās no 3,5 līdz 5,8. Katru pazīmi novērtēja pēc skalas no 0 līdz 3 ballēm: 0 - pazīme neeksistē, 2 - pazīme izteikta mēreni, 3 - pazīme izteikta spēcīgi. Vērtēja strukturālo izmaiņu datus un veica ādas imunitātes vērtējumu: veica histoloģiskos pētījumus, izmantojot gaismas mikroskopiju. Gaismas mikroskopijas palielinājums - 400 reizes, ar imūnhistoķīmijas metožu palīdzību, lietojot CDla, CD31, CD34, CD3, CD8. 2. tabula - ar metabolisko sindromu sirgstošu abu pacientu grupu klīnisko pētījumu rezultāti. 2. tabula 1. grupa, jaunais krēms, n=12 2. grupa, krēmu neizmanto, n=15 Ādas turgors (pēc skalas 0-1-2-3) vidējs, augsts vidējs, zems Mitrinājums Transepidermālais ūdems zudums un komeometrija 27,2±1,1 19,1 ±1,2 Lobīšanās (pēc skalas 0-1-2-3) Vidējais indekss 1,8 Lielo suņu daudzums 34,4% Vidējais indekss 2,6 Lielo šūnu daudzums 65,7+5% Lentigo, pigmentācijas nevienmērīgums (pēc skalas 0-1-2-3) Vidējais indekss 1,2 Vidējais indekss 2,8 pH Robežās 5,5-5,8 Robežās 5,4-5,6 Ādas reljefs (pec skalas 0-1-2-3) Vidējais indekss 1,6 Vidējais indekss 2,8 14Clinical studies included anthropometric data (body mass index, waist circumference, arterial blood pressure), blood test (glucose, lipoproteins). To evaluate the epidermal lipid barrier of the skin, siaskopy and dermatoscopy were performed (mole MoleVievv SIAscope V Handset, Astron, UK and the dermatoscope HEINE alpha + Heine Optotechnic, Germany). The states of skin relief and morphology (turgor, microrelief and the presence of papillomas) were evaluated by dermatoscopy 13 13LV 15082. Pigmentation and peeling were evaluated using siachopy. p-metric measurements were performed with a pH-meter. Measurements of transepidermal water loss were performed with the help of the Tewameter® TM 300, Courage + Khazaka eleclronic GmbH, Germany (camelmeter). The calculation and retention of the study results obtained with these sensors was performed using the software in the database SPSS 20.0 {Microsoft, USA). The results were recorded in numerical values. The range of normal values for corneometry values ranged from 40 and higher, camelmeters below 12, pH-metrics from 3.5 to 5.8. Each attribute was rated on a scale from 0 to 3: 0 - no sign, 2 - sign moderate, 3 - sign strong. Evaluation of structural change data and assessment of skin immunity: histological studies were performed using light microscopy. Magnification of light microscopy - 400 times, by immunohistochemical methods using CDla, CD31, CD34, CD3, CD8. Table 2 - Results of clinical trials of both groups of patients with metabolic syndrome. Table 2 Group 1, New Cream, n = 12 Group 2, No Cream, n = 15 Skin Markers (0-1-2-3 scale) Medium, Medium, Low Moisture Transepidermal Water Loss and Cometry 27, 2 ± 1.1 19.1 ± 1.2 Hatching (by scale 0-1-2-3) Average Index 1.8 Large Dogs 34.4% Average Index 2.6 Large Cells 65.7 + 5% Lentigo, unevenness of pigmentation (by scale 0-1-2-3) Average index 1.2 Average index 2.8 pH Within limits 5.5-5.8 Within limits 5.4-5.6 Skin relief (on scale 0-1 -2-3) Average Index 1.6 Average Index 2.8 14

Veicot pētījumu, vairumam pacientu no abām grupām, noteica sūdzības par ādas sausumu un pastiprinātu lobīšanos.In the study, most patients in both groups were complaining of dry skin and increased peeling.

Klīnisko pētījumu rezultātā 1. grupas pacientiem (12), kuri lietoja jaumo krēmu 2 mēnešus, tika iegūti šādi rādītāji: 1) ādas mitrums bija 27, 2±1, t.i., augstāks, salīdzinot ar 2. grupas pacientiem (15) - 19,1±1,2; 2) lobīšanās - 1,8 bija 1. grupas pacientiem un 2,6 - 2. grupas pacientiem, t.i., lobīšanās bija vairāk izteikta 2. grupas pacientiem; 3) pigmentācija - 1,2 bija 1. grupas pacientiem un 2,8 - 2. grupas pacientiem, t.i., pigmentācija bija vairāk izteikta 2. grupas pacientiem; 4) ādas reljefs - 1,6 bija 1. grupas pacientiem un 2,8 bija 2. grupas pacientiem, t.i., papilomu esamība un ādas elastoze bija vairāk izteikta 2. grupas pacientiem. Tādējādi 1. grupas pacientiem, kuri lietoja jauno krēmu 2 mēnešu laikā, konstatēja ādas barjerfunkcijas stāvokļa, ādas reljefa un elastības atjaunošanos.As a result of clinical studies, patients of Group 1 patients (12) who took cream for 2 months received the following indicators: 1) skin moisture was 27, 2 ± 1, ie higher than in group 2 patients (15) - 19, 1 ± 1.2; 2) peeling 1.8 was in group 1 patients and 2.6 in group 2 patients i.e. peeling was more pronounced in group 2 patients; 3) pigmentation - 1.2 was in group 1 patients and 2.8 - in group 2 patients, i.e. pigmentation was more pronounced in group 2 patients; 4) skin relief - 1.6 was in group 1 patients and 2.8 was in group 2 patients, i.e. the presence of papillomas and skin elasticity was more pronounced in group 2 patients. Thus, patients in Group 1 who took the new cream within 2 months showed a restoration of skin barrier function, skin relief, and elasticity.

Saskaņā ar datiem, kas iegūti pētot ādas imunitāti, ādas imunitātes šūnu (Langerhansa šūnas) aktivitāte 2. grupas pacientiem bija pazemināta. Turklāt 2. grupas pacientu ādā bija novērojama limfocitārā infiltrācija un Birbeka granulu uzkrāšanās (liecina par iekaisuma procesu). 1. grupas pacientu ādā jaunā krēma lietošanas fonā pieauga imūnkompetento Langerhansa šūnu daudzums, par divām reizēm samazinājās Birbeka granulu skaits, kas liecināja par vietējās ādas imunitātes uzlabošanos.According to data from skin immunity studies, the activity of skin immune cells (Langerhans cell) was reduced in group 2 patients. In addition, lymphocytic infiltration and accumulation of Birbek pellets were observed in the skin of patients in Group 2 (indicative of an inflammatory process). In the skin of Group 1 patients, the number of immunocompetent Langerhans cells increased in the background of the use of the new cream, and the number of Birbeka pellets decreased two times, suggesting an improvement in local skin immunity.

Veiktie pētījumi pierādīja, ka jaunajam krēma sastāvam piemīt kosmētiskās un ārstnieciski-profilaktiskās īpašības, tas atjauno ādas epidermālo lipīdu barjeru un ādas baņcrfunkciju pacientiem ar metabolisko sindromu: uzlabo ādas turgoru un mitruma stāvokli, atjauno elastību un ādas gludo reljefu, samazina pigmentācijas izpausmes, iekaisuma papilomas.Studies have shown that the new cream composition has cosmetic and curative-prophylactic properties, restores skin epidermal lipid barrier and skin function in patients with metabolic syndrome: improves skin turgor and moisture, restores elasticity and smooth skin texture, reduces pigmentation, inflammation papillomas, inflammatory papillomas .

Izgudrojuma sarežģītība saistīta ar to, ka nebija zināmi jaunā sastāva komponenti un to savstarpējā attiecība, līdz ar kuriem jaunais sastāvs varētu veikt efektīvu atjaunojošu iedarbību uz ādas epidermālo lipīdu barjeru. Krēma izstrādāšanu papildus sarežģīja apstāklis, ka jaunā sastāva komponenti bija gan hidrofilas (selēnmetionīns), gan hidrofobas (E vitamīns, skvalāns) vielas. Nebija zināmi apstākļi, kuros jaunā sastāva hidrofilie un hidrofobie komponenti varētu būt savienojami vienā krēmā, kuram piemīt augsta taukainības pakāpe. Eksperimentāli iegūtie komponenti, to savstarpējā attiecība un jaunā krēma sastāva iegūšanas 15 15LV 15082 tehnoloģiskie apstākļi ļāva izgatavot stabilu homogēnu jaunā krēma sastāvu, kas saglabā savu efektivitāti un stabilu konsistenci istabas temperatūrā 6-8 mēnešu laikā.The complexity of the invention is due to the fact that the new composition components and their interrelationship were not known, so that the new composition would have an effective rejuvenating effect on the epidermal lipid barrier of the skin. The addition of the cream was further complicated by the fact that the components of the new composition were both hydrophilic (selenomethionine) and hydrophobic (vitamin E, squalane) substances. There were no circumstances in which the hydrophilic and hydrophobic components of the new composition could be combined in one cream with a high degree of grease. The experimental components, their relationship and the technological conditions of the new cream 15 15LV 15082 made it possible to produce a stable homogeneous composition of the new cream, which maintains its efficiency and stable consistency at room temperature for 6-8 months.

Jaunā krēma sastāvs ir ūdens un tauku, taukveidīgu un citu vielu maisījums. Augstais lauku sastāva un taukveidīgu vielu procentuālais sastāvs svarīgs, lai sasniegtu ādas epidermālās lipīdu barjeras un ūdens-lipīdu mantijas atjaunošanas efektu. Pastāv tehnoloģiskas grūtības, savienojot tādu skaitu taukvielu, bez gatavā produkta noslāņošanās riska. Šāda tipa krēmiem ir svarīgi lietot īpašus emulgatorus, kuru iekļaušana pieteiktajā attiecībā ļauj iegūt jaunā krēma sastāva vienmērigu krēmveida konsistenci, kas saglabā stabilitāti uzglabāšanas procesā un gatavās zāļu formas ērtu ekstrūziju no iepakojuma (tūbas), kas ļoti svarīgi pacienta lietošanas ērtībai. Pieteiktā jaunā krēma sastāva atšķirīgās īpatnības ir tajā apstāklī, ka par emulgatoriem tiek izmantotas vairākas vielas, katrai no tām piemīt struktūrveidojošas un emulģējošas īpašības. Vienlaikus lietotie emulgatori, kurus ievada krēma sastāvā stingri noteiktā secībā, saskaņā ar pieteiktā izgudrojuma tehnoloģiju nodrošina efektīvu un stabilu jaunā krēma kompleksā sastāva saglabāšanu. Hidrofilo komponentu (ūdens, selēnmetionīns, glicerīns) noteikta savstarpējā attiecība un šķīdinātāju (cetilspirts, glicerīns) noteikta savstarpējā attiecība ļauj saglabāt hidrofilo (selēnmetionīns) un hidrofobo (tokoferols, skvalāns, trigliceridi) vielu aktivitāti, kuras iekļautas krēma kompozīcijas sastāvā.The composition of the new cream is a mixture of water and fat, fat and other substances. The high percentage of field composition and fatty substances is important in achieving the skin's epidermal lipid barrier and water-lipid restoration effect. There are technological difficulties in connecting such a quantity of fat without the risk of stratification of the finished product. For these types of creams, it is important to use special emulsifiers, the inclusion of which in the proposed application allows to obtain a smooth creamy consistency of the new cream composition, which preserves the stability of the storage process and easy extrusion of the finished dosage form from the package (tubes), which is very important for the convenience of the patient. The different peculiarities of the composition of the new cream applied are the fact that several substances are used as emulsifiers, each of them has structuring and emulsifying properties. At the same time, emulsifiers used in the composition of the cream in a strictly defined order, in accordance with the technology of the claimed invention, provide an effective and stable preservation of the complex composition of the new cream. A certain ratio of hydrophilic components (water, selenomethionine, glycerol) and the ratio of solvents (cetyl alcohol, glycerol) to the activity of hydrophilic (selenomethionine) and hydrophobic (tocopherol, squalane, triglycerides) included in the composition of the cream composition.

Jaunā krēma sastāvs netika konstatēts zinātniski tehniskās un patentu informācijas avotos. Veiktie eksperimentālie un klīniskie pētījumi liecina, par atbilstību kritērijam «izgudrojuma līmenis”The composition of the new cream was not found in scientific-technical and patent information sources. Experimental and Clinical Trials Completed to the 'Invention Level' Criterion

RŪPNIECISKĀ IZMANTOŠANAINDUSTRIAL USE

Izstrādātas 2 rūpnieciskās krēma formas - 65,0 g (pa 30,0 g) gaismas necaurlaidīgās alumīnija tūbās. Abu jaunā krēma sastāva formu stabilitāte un tehnoloģiskās īpašības saglabājas 6 mēnešu laikā istabas temperatūrā.Developed in 2 industrial cream shapes - 65.0 g (30.0 g) in opaque aluminum tubes. Stability and technological properties of both forms of the new cream remain for 6 months at room temperature.

Informācijas avoti 1. http://www.polismrd.com/articles-metabolicheskijj-prichiny-simptomy-i-priznaki.html., 08.07.2015. 2. Pat. Ru 2182822, Cl, 2002, A61K9/06; A61P17/02. 3. http://cosmocat.ru/publ/4-l-0-428, 08.07.2015. 4. http://www.frauleto.ru/articles/ceramidv-i-kozha/, 08.07.2015. 16 5. http:/Amari.ru/tematicheskie-stati/zdorove/immunitetJkozhi.html, 08.07.2015. 6. Van Hattem S, Bootsma AH, Thio HB. Skin manifestations of diabetes. Cleve Clin J Med. 2008;75:772,774, 776-777. doi: 10.3949/ccjm.75.11.772. passīm. 7. Elias, PM, Holleran, WM, Calhouti, CJ, Quiec, D, Brovvn, BE, Bekne, M, Feingold, KR: Permeability barrier homeostasis. The role of lipid processing. In: Loden M, Maibach HI (eds). Dry Skin and Moisturizers: Chemistry and Function. 2000 Dermatology: Clinical and Basic Science Series. New York: CRC Press, p 59-70. 8. Fluhr JW, Feingold KR, Elias PM. Transcpidermal watcr loss rcflects penneability barrier status: validation in human and rodent in vivo and ex vivo models. Exp Dermatol 2006; 15:483-492. 9. Fluhr JW, Elias PM. Stratum comeum pH: Formation and function of the ’acid mantle'. Exog. Dermatol. 1,163-175(2002). 10. Serup J, et al., eds. Handbook of non-invasive methods and the skin. 2nd ed. CRC press, 2006. 11. Wilhelm K-P, et al., eds. Bioengineering of the skin: skin imaging and analysis. 2nd ed., 2007. 12. Pat. JP 2013516441, A, 2013, A61K8/97, A61Q19/00. 13. Pat. US 2013129803, A, 2013, A61K8/97, A61Q19/00. 14. Pat. RU 2458676, C2,2012, A61K8/97, A61Q19/00. 15. Bissett DL, Chatterjee R, Hannon DP. Photoprotective effect of superoxide-scavenging antioxidants against ultraviolet radiation-induced chronic skin damage in the hairless mouse. Photodermatol Photoimmimol Photomed. 1990;7:56-62. 16. Burke KE, Clive J, Combs GF, Jr, Commisso J, Keen CL, Nakamura RM. Effects of topical and oral vitamin E on pigmentation and skin cancer induced by ultraviolet irradiation in Skh:2 hairless mice. Nutr Cancer. 2000;38:87-97. doi: 10.1207/S15327914NC38113. 17. Chen L, Hu JY, Wang SQ. The role of antioxidants in photoprotection: a critical review. J Am Acad Dermatol. 2012;67:1013-1024. doi: 10.1016/j.jaad.2012.02.009. 18. Bikle D, Teichert A, Hawker N, Xie Z, Oda Y. Sequential regulation of keratinocyte differentiation by l,25(OH)2D3, VDR, and its coregulators. J Steroid Biochem Mol Biol. 2007;103:396-404. doi: 17 17LV 15082 10.1016/j .jsbmb.2006.12.063. 19. Takema Y, Hattori M, Aizawa K. The relationship between quantitative changes in collagen and formation of vvrinkles on hairless mouse skin after chronic UV irradiation. J Dermatol Sci. 1996;12:56-63. doi: 10.1016/0923-1811(95)00467-X. 20. Sardy M. Role of matrix metalloproteinases in skin ageing. Connect Tissue Res. 2009;50:132-138. doi: 10.1080/03008200802585622. 21. Steenvoorden DP, Beijersbergen van Henegouwen G. Protection againsL UV-induced systemic immunosuppression in mice by a single topical application of the antioxidant vitamīns C and E. Int J Radiat Biol. 1999;75:747-755. doi: 10.1080/095530099140096. 22. Van de Kerkhof PC. Update on retinoid therapy of psoriasis in: an update on the use of retinoids in dermatology. Dermatol Ther. 2006;19:252-263. 23. Burke The effects of topical L-selenomethionine on protection against UVB-induced skin cancer when given before, during, and after UVB exposure//J Drugs Dermatol 2014 Oct;13(10):1214-23. 24. Kircik LH, Del Rosso JQ, Aversa D. Evaluating Clinical Use of a Ceramide-dominant, Physiologic Lipid-based Topical Emulsion for Atopic Dermatitis. J Clin Aesthet Dermatol. 2011;4:34-40. 25. Callen J, Chamlin S, Eichenfield LF, et al A systematic review of the safety of topical therapies for atopic dermatitis. Br J Dermatol. 2007 Feb;156(2):203-21. Revievv. PubMed PMID: 17223859. 26. Loden M. Role of topical emollients and moisturizers in the treatment of dry skin barrier disorders// Am J Clin Dermatol. 2003;4(11):771-88. 27. Jurkievvicz BA, Bissett DL, Buettner GR. Effect of topically applied tocopherol on ultraviolet radiation-mediated ffee radical damage in skin. J Invest Dermatol. 1995;104:484-488, 28. http://www.vaseline.us, 08.07.2015. 29. http://www.faqs.org/patents/app/20080319069,08.07.2015. 30. http://www.roz.ru/selena/, 08.07.2015. 31. Verdier-Sevrain S, Bonte F. Skin hydration: a review on its molecular mechanisms. J Cosmet Dermatol 2007; 6: 75-82. 32. Pat. KR 101504908, Bl, 2015, A61K8/97. 33. Pat. KR 20140148149, A, 2014, A61K8/97; A61P17/00. 18 34. Pat. KR 20150008825, A, 2015, A61K8/14; A61Q19/00. 35. Pat. KR 20150011324, A, 2015, A61K8/97; A61Q19/00. 36. Pat. WO 2015013634, A, 2015, A61K8/68; A61Q19/00. 37. http://www.drugs.coin/mtm/selenium-sulfide-topical.html, 08.07.2015. 38. Wu L, Huang ZH, Burau RG. Selenium accumulation and selenium-salt cotolerance in five grass species. Crop Sci. 1988;28:517-522. 39. Squalane: the natūrai moisturizer", by Rosenthal, Maurice L. in Chemistry and Manufacture of Cosmetics (3rd Edition), Editor: Schlossman, Mitchell L. (2002), 3(Bk. 2), 869-875. 40. Final report on the safety assessment of squalane and squalene". Journal of the American College of Toxicology 1 (2): 37-56. 1982. 41. http://www.drugs.com/mmx/alpha-tocopherol.html, 08.07.2015. 42. Soni MG, Taylor SL, Greenberg NA, Burdock GA (October 2002). "Evaluation of the health aspects of methyl paraben: a review of the published literature". Food Chem. Toxicol. 40 (10): 1335-73. 43. Jens Rirk T.auridsen (1976). "Food emulsifiers: Surface activity, edibility, manufacture, composition, and application". Journal of the American Oil Chemists' Society 53 (6): 400-407. 44. Ballmann C, Mueller BW. Stabilizing effect of cetosteaiyl alcohol and glyceryl monostearate as co-emulsifiers on hydrocarbon-fi:ee 0/W glyceride creams. Pharm Dev Technol. 2008;13(5):433-45. 45. Akoh, Casimir C. (2006). Handbook of Functional Lipids. Washington, DC: Taylor & Francis. 46. http://www.drugs.com/sfx/vaseline-dermatology-fonnula-side-efFects.html, 08.07.2015. 47. W. Sterry, R. Paus, W, Burgdorf; Dermatology, Stuttgart [etc.] : Thieme, 2006, p. 586. 48. Ullmann's Encyclopedia of Industrial Chemistry. Copyright © 1999-2014 by John Wiley and Sons, Inc.Sources of Information 1. http://www.polismrd.com/articles-metabolicheskijj-prichiny-simptomy-i-priznaki.html., 08.07.2015. 2. Pat. Ru 2182822, Cl, 2002, A61K9 / 06; A61P17 / 02. 3. http://cosmocat.ru/publ/4-l-0-428, 08.07.2015. 4. http://www.frauleto.ru/articles/ceramidv-i-kozha/, 08.07.2015. 16 5. http: /Amari.ru/tematicheskie-stati/zdorove/immunitetJkozhi.html, 08.07.2015. 6. Van Hattem S, Bootsma AH, Thio HB. Skin manifestations of diabetes. Cleve Clin J Med. 2008; 75: 772,774, 776-777. doi: 10.3949 / ccjm.75.11.772. passports. 7. Elias, PM, Holleran, WM, Calhouti, CJ, Quiec, D, Brovvn, BE, Bekne, M, Feingold, KR: Permeability barrier homeostasis. The role of lipid processing. In: Loden M, Maibach HI (eds). Dry Skin and Moisturizers: Chemistry and Function. 2000 Dermatology: Clinical and Basic Science Series. New York: CRC Press, pp. 59-70. 8. Fluhr JW, Feingold KR, Elias PM. Transcpidermal watcr loss rcflects penneability barrier status in vivo and ex vivo models. Exp Dermatol 2006; 15: 483-492. 9. Fluhr JW, Elias PM. Stratum comeum pH: Formation and function of the acid mantle. Exog. Dermatol. 1.163-175 (2002). 10. Serup J, et al., Eds. Handbook of non-invasive methods and the skin. 2nd ed. CRC press, 2006. 11. Wilhelm K-P, et al., Eds. Bioengineering of the skin: skin imaging and analysis. 2nd ed., 2007. 12. Pat. JP 2013516441, A, 2013, A61K8 / 97, A61Q19 / 00. 13. Pat. US 2013129803, A, 2013, A61K8 / 97, A61Q19 / 00. 14. Pat. RU 2458676, C2,2012, A61K8 / 97, A61Q19 / 00. 15. Bissett DL, Chatterjee R, Hannon DP. Photoprotective effect of superoxide scavenging antioxidants against ultraviolet radiation-induced chronic skin damage in the hairless mouse. Photodermatol Photoimmimol Photomed. 1990; 7: 56-62. 16. Burke KE, Clive J, Combs GF, Jr., Commisso J, Keen CL, Nakamura RM. Effects of topical and oral vitamin E is a pigmentation and skin cancer induced by ultraviolet irradiation in Skh: 2 hairless mice. Nutr Cancer. 2000; 38: 87-97. doi: 10.1207 / S15327914NC38113. 17. Chen L, Hu JY, Wang SQ. The role of antioxidants in photoprotection: a critical review. J Am Acad Dermatol. 2012; 67: 1013-1024. doi: 10.1016 / Jan. 2012.02.009 18. Bikle D, Teichert A, Hawker N, Xie Z, Oda Y. Sequential regulation of keratinocyte differentiation by 1, 25 (OH) 2D3, VDR, and its coregulators. J Steroid Biochem Mol Biol. 2007; 103: 396-404. doi: 17 17LV 15082 10.1016 / j .jsbmb.2006.12.063. 19. Takema Y, Hattori M, Aizawa K. J Dermatol Sci. 1996; 12: 56-63. doi: 10.1016 / 0923-1811 (95) 00467-X. 20. Sardy M. Role of matrix metalloproteinases in skin aging. Connect Tissue Res. 2009; 50: 132-138. doi: 10.1080 / 03008200802585622. 21. Steenvoorden DP, Beijersbergen van Henegouwen G. Protection AgainsL UV-induced systemic immunosuppression in mice by a single topical application of the antioxidant vitamin C and E. Int J Radiat Biol. 1999; 75: 747-755. doi: 10.1080 / 095530099140096. 22. Van de Kerkhof PC. Update is a retinoid therapy of psoriasis in the dermatology. Dermatol Ther. 2006; 19: 252-263. 23. Burke The effects of topical L-selenomethionine on protection against UVB-induced skin cancer when given before, and after UVB exposure // J Drugs Dermatol 2014 Oct; 13 (10): 1214-23. 24. Kircik LH, Del Rosso JQ, Aversa D. Evaluating Clinical Use of a Ceramide-dominant, Physiologic Lipid-based Topical Emulsion for Atopic Dermatitis. J Clin Aesthet Dermatol. 2011; 4: 34-40. 25. Callen J, Chamlin S, Eichenfield LF, et al. A systematic review of the topical therapies for atopic dermatitis. Br J Dermatol. 2007 Feb 156 (2): 203-21. Revievv. PubMed PMID: 17223859. 26. Loden M. Role of topical emollients and moisturizers in the treatment of dry skin barrier disorders // Am J Clin Dermatol. 2003; 4 (11): 771-88. 27. Jurkievvicz BA, Bissett DL, Buettner GR. Effect of topically applied tocopherol is ultraviolet radiation-mediated ffee radical damage in skin. J Invest Dermatol. 1995; 104: 484-488, 28. http://www.vaseline.us, 08.07.2015. 29. http://www.faqs.org/patents/app/20080319069,08.07.2015. 30. http://www.roz.ru/selena/, 08.07.2015. 31. Verdier-Sevrain S, Bonte F. Skin hydration: a review on its molecular mechanisms. J Cosmet Dermatol 2007; 6: 75-82. 32. Pat. KR 101504908, B1, 2015, A61K8 / 97. 33. Pat. KR 20140148149, A, 2014, A61K8 / 97; A61P17 / 00. 18 34. Pat. KR 20150008825, A, 2015, A61K8 / 14; A61Q19 / 00. 35. Pat. KR 20150011324, A, 2015, A61K8 / 97; A61Q19 / 00. 36. Pat. WO 2015013634, A, 2015, A61K8 / 68; A61Q19 / 00. 37. http: //www.drugs.coin/mtm/selenium-sulfide-topical.html, 08.07.2015. 38. Wu L, Huang ZH, Burau RG. Selenium accumulation and selenium salt in five grass species. Crop Sci. 1988; 28: 517-522. 39. Squalane: the kind of moisturizer, "by Rosenthal, Maurice L., in Chemistry and Manufacture of Cosmetics (3rd Edition), Editor: Schlossman, Mitchell L. (2002), 3 (Bk. 2), 869-875. 40. Final report on squalane and squalene ". Journal of the American College of Toxicology 1 (2): 37-56. 1982. 41. http://www.drugs.com/mmx/alpha-tocopherol.html, 08.07.2015. 42. Soni MG, Taylor SL, Greenberg NA, Burdock GA (October 2002). " Evaluation of the published literature ". Food Chem. Toxicol. 40 (10): 1335-73. 43. Jens Rirk T.Auridsen (1976). " Food emulsifiers: Surface activity, edibility, manufacture, composition, and application ". Journal of the American Oil Chemists' Society 53 (6): 400-407. 44. Ballmann C, Mueller BW. Stimulating effect of cetosteaeyl alcohol and glyceryl monostearate as co-emulsifiers is hydrocarbon-ene 0 / W glyceride creams. Pharm Dev Technol. 2008; 13 (5): 433-45. 45. Akoh, Casimir C. (2006). Handbook of Functional Lipids. Washington, DC: Taylor & Francis. 46. http://www.drugs.com/sfx/vaseline-dermatology-fonnula-side-efFects.html, 08.07.2015. 47. W. Sterry, R. Paus, W, Burgdorf; Dermatology, Stuttgart [etc.]: Thieme, 2006, p. 586. 48. Ullmann's Encyclopedia of Industrial Chemistry. Copyright © 1999-2014 by John Wiley and Sons, Inc.

Claims (2)

PRETENZIJAS 1. Krēms sejas ādas, kakla un dekoltē zonas epidermālās lipīdu barjeras atjaunošanai pacientiem ar metabolisko sindromu raksturīgs ar to, ka satur selēn-L-metionīnu, a-tokoferola acetātu, skvalānu, metil-4-hidroksibenzoātu, glicerīna monostearātu 60, cetilspirtu, vidēji garo ķēžu triglicerīdus, balto vazelīnu, makrogola-20-glicerīna monostearātu, 1,2-propāndiolu un attīrītu ūdeni.CLAIMS 1. Cream for rejuvenation of the epidermal lipid barrier in the facial skin, neck and décolleté regions in patients with metabolic syndrome is characterized by containing selenium-L-methionine, α-tocopherol acetate, squalane, methyl 4-hydroxybenzoate, glycerol monostearate 60, cetyl alcohol, medium-chain triglycerides, white petroleum jelly, macrogol-20-glycerin monostearate, 1,2-propanediol and purified water. 2. Krēms sejas ādas, kakla un dekoltē zonas epidermālās lipīdu barjeras atjaunošanai pacientiem ar metabolisko sindromu saskaņā ar pirmo pretenziju atšķiras ar to, ka satur selēn-L-metionīnu, α-tokoferola acetātu, skvalānu, metiMl-hidroksibenzoātu, glicerīna monostearātu 60, cetilspirtu, vidēji garo ķēžu triglicerīdus, balto vazelīnu, makrogola-20-glicerīna monostearātu, 1,2-propāndiolu un attīrītu ūdeni šādās komponentu masas attiecībās g (%): selēn-L-metionīns 0,0005-0,0015; α-tokoferola acetāts 0,50-1,50; skvalāns 11,25-18,75; metil-4- hidroksibenzoāts 0,05 0,15; glicerīna monostearāts 60 2,52-4,20; cctilspirts 3,78-6,29; vidēji garo ķēžu trigliceiīdi 4,72-7,87; baltais vazelīns 16,05-26,74; makrogols-20-gliceriha monostearāts 4,40-7,34; 1,2—propāndiols 6,29-10,49; attīrīts ūdens līdz 100,0.2. The cream for the regeneration of the epidermal lipid barrier in the face, neck and décolleté area of patients with metabolic syndrome according to the first claim, comprising selenium-L-methionine, α-tocopherol acetate, squalane, methylmyl-hydroxybenzoate, glycerol monostearate 60, cetyl alcohol. , medium chain triglycerides, white petroleum jelly, macrogol-20-glycerin monostearate, 1,2-propanediol and purified water in the following component weight ratios g (%): selenium-L-methionine 0.0005-0.0015; α-tocopherol acetate 0.50-1.50; squalane 11,25-18,75; methyl 4-hydroxybenzoate 0.05 0.15; glycerol monostearate 60 2.52-4.20; ctyl alcohol 3.78-6.29; medium long chain triglycerides 4.72-7.87; White Vaseline 16.05-26.74; macrogol-20-glycerol monostearate 4.40-7.34; 1,2-propanediol 6.29-10.49; purified water to 100.0.
LVP-15-90A 2015-08-24 2015-08-24 Cream for restoring epidermal lipid barrier of the facial skin, neck and decollette area in metabolic syndrome patients LV15082B (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
LVP-15-90A LV15082B (en) 2015-08-24 2015-08-24 Cream for restoring epidermal lipid barrier of the facial skin, neck and decollette area in metabolic syndrome patients
PCT/LV2015/000006 WO2017034384A1 (en) 2015-08-24 2015-08-25 Epidermal lipid barrier restoring cream for facial skin, neck and decollete area for metabolic syndrome patients
EP15902371.2A EP3439616A4 (en) 2015-08-24 2015-08-25 Epidermal lipid barrier restoring cream for facial skin, neck and decollete area for metabolic syndrome patients

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
LVP-15-90A LV15082B (en) 2015-08-24 2015-08-24 Cream for restoring epidermal lipid barrier of the facial skin, neck and decollette area in metabolic syndrome patients

Publications (2)

Publication Number Publication Date
LV15082A true LV15082A (en) 2015-12-20
LV15082B LV15082B (en) 2016-04-20

Family

ID=54846286

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-15-90A LV15082B (en) 2015-08-24 2015-08-24 Cream for restoring epidermal lipid barrier of the facial skin, neck and decollette area in metabolic syndrome patients

Country Status (3)

Country Link
EP (1) EP3439616A4 (en)
LV (1) LV15082B (en)
WO (1) WO2017034384A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6992057B2 (en) 2016-06-10 2022-01-13 クラリティ コスメティックス インコーポレイテッド Non-acne-forming hair and scalp care products and how to use them

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3879470D1 (en) * 1988-04-08 1993-04-22 Stada Arzneimittel Ag AMBIPHILE CREAM.
US6630442B1 (en) * 1997-01-10 2003-10-07 Theodore Hersh Reparatives for chemosurgery and laser (thermal) therapy
WO2001017484A2 (en) * 1999-09-07 2001-03-15 D.T.R. Dermal Therapy Research Inc. Topical urea composition

Also Published As

Publication number Publication date
WO2017034384A1 (en) 2017-03-02
EP3439616A4 (en) 2020-03-04
EP3439616A1 (en) 2019-02-13
LV15082B (en) 2016-04-20

Similar Documents

Publication Publication Date Title
CA2907495C (en) Antioxidant compositions and methods of using the same
Wan et al. Moisturizing different racial skin types
US20240197677A1 (en) Putrescine slow-release topical formulations
KR20190101948A (en) Composition for prevention or treatment of inflammatory skin diseases or severe pruritus comprising the aqueous solubilized ursodeoxycholic acid
Altuntaş et al. Anti-aging potential of a cream containing herbal oils and honey: Formulation and in vivo evaluation of effectiveness using non-invasive biophysical techniques
AU2002318699B2 (en) Cream for treatment of skin injured by the sun
Piccioni et al. Improving skin aging, skin hydration and sensitive skin with four specific skin care products: results from a single-centre, observational, prospective study
AU2002318699A1 (en) Cream for treatment of skin injured by the sun
Mehlich et al. Acidification of the skin and maintenance of the physiological skin pH value by buffered skin care products formulated around pH 4
LV15082A (en) Cream for restoring epidermal lipid barrier of the facial skin, neck and decollette area in metabolic syndrome patients
US7306810B1 (en) Skin cream
US20230000759A1 (en) Ppar agonist complex and methods of use
WO2020201377A1 (en) Cream for treatment of skin injured by the sun
JP4488933B2 (en) Wrinkle improving agent and external composition for skin
KR100574850B1 (en) Skin care composition containing synthetic palmitoyl pentapeptide
Kyi A Split-face Double-blind Randomized Placebo-controlled Trial of the Efficacy of Kakadu Plum Extract for Reduction of Periorbital Wrinkles
Natasia et al. Test the Potential of Macadamia Nut Oil (Macadamia F. Muell) as Sunscreen in Cream Preparations in Vitro
Clarys et al. 27 New Trends in Antiaging Cosmetic Ingredients and Treatments: An Overview
Somwanshi et al. Cosmetic Science
WO2023247838A1 (en) Cosmetic or dermatological composition comprising polylysine dendrimers and use thereof
KR100355953B1 (en) Skin Care Composition Containing Ursolic Acid and Synthetic Palmitoyl Pentapeptide
CN118526430A (en) A compact anti-aging essential oil containing camellia seed oil extract and its preparation method
BRPI1107447A2 (en) Cosmetic makeup, skin care kit, method for treating oily or mixed skin or acne skin
UHODA et al. DRY SKIN IN DIABETIC PATIENTS
Botha The stabilising effect of met [h] ylsulfonylmethane (MSM) on urea containing formulations